Psyma International Medical Reorganized
Psyma’s international medical market research business is undergoing reorganization, in order to meet the demand for an ever more globally oriented scope of services and expertise. The restructuring also prepares for the transition from Psyma International Medical’s founder, Matthias Fargel, who is handing over the strategic leadership of the worldwide Psyma HealthCare activities to Jeff Judek, presently COO of Psyma International USA, by the end of this year.
Left:
Matthias Fargel, Founding Managing Director of Psyma International Medical, Germany
Right:
Jeff Judek, Managing Director Psyma USA
Psyma operates main hubs for healthcare studies in Shanghai, Moscow, Nuremberg, Madrid, São Paulo, Philadelphia and Mexico City. Cross-national “Center of Excellence“ teams devote themselves – on top of our standard range of services – to specific markets like oncology, virology, biologicals/biosimilars, orphan drugs, medical technology and vaccinations.
In all countries, the domestic and international business units are now merged. The Germany based office in Nuremberg is directed by Dr. Hubertus Meixner, supported by Mr. Marian Mihelic, Director Market Development & Consulting. This strategic reorganization enables Psyma to offer its clientele an even broader spectrum of global and regional expertise with integrated resources in the European, Asian, North and Latin American markets.
(Left: Dr. Hubertus Meixner, Managing Director Psyma International Medical
Right: Marian Mihelic, Director Market Development & Consulting)